US Drug Recall Register

FDA Drug Recalls

2,277 recalls · Class II, newest first

Class II · Moderate risk Ongoing

Lacosamide Tablets

Reason CGMP Deviations

Glenmark Pharmaceuticals Inc., USA NDC 68462-679-60 D-0330-2025
Class II · Moderate risk Ongoing

Fluphenazine Hydrochloride Tablets

Reason CGMP Deviations

Glenmark Pharmaceuticals Inc., USA NDC 68462-338-01 D-0326-2025
Class II · Moderate risk Ongoing

Pravastatin Sodium Tablets 80mg

Reason CGMP Deviations

Glenmark Pharmaceuticals Inc., USA NDC 68462-198-90 D-0325-2025
Class II · Moderate risk Ongoing

Rufinamide Tablets 200mg

Reason CGMP Deviations

Glenmark Pharmaceuticals Inc., USA NDC 68462-713-08 D-0323-2025
Class II · Moderate risk Ongoing

Lacosamide Tablets 200mg

Reason CGMP Deviations

Glenmark Pharmaceuticals Inc., USA NDC 68462-681-60 D-0321-2025
Class II · Moderate risk Ongoing

Gabapentin Tablets 600mg

Reason CGMP Deviations

Glenmark Pharmaceuticals Inc., USA NDC 68462-126-05 D-0320-2025
Class II · Moderate risk Ongoing

Voriconazole Tablets 50mg

Reason CGMP Deviations

Glenmark Pharmaceuticals Inc., USA NDC 68462-572-30 D-0319-2025
Class II · Moderate risk Ongoing

Voriconazole Tablets 200 mg

Reason CGMP Deviations

Glenmark Pharmaceuticals Inc., USA NDC 68462-573-30 D-0318-2025
Class II · Moderate risk Ongoing

Solifenacin Succinate Tablets 10MG

Reason CGMP Deviations

Glenmark Pharmaceuticals Inc., USA NDC 68462-387-30 D-0317-2025
Class II · Moderate risk Ongoing

Fenofibrate Capsules 67 mg

Reason CGMP Deviations

Glenmark Pharmaceuticals Inc., USA NDC 68462-580-01 D-0314-2025
Class II · Moderate risk Ongoing

GreenScreen

Reason cGMP deviations

Kabana Skin Care D-0514-2025
Class II · Moderate risk Ongoing

Erin's Faces

Reason cGMP deviations

Kabana Skin Care D-0513-2025
Class II · Moderate risk Ongoing

B Natural Organics

Reason cGMP deviations

Kabana Skin Care D-0512-2025
Class II · Moderate risk Ongoing

chlorproMAZINE Hydrochloride Tablets

Reason CGMP deviations: presence of N-Nitroso-Desmethyl Chlorpromazine impurity above the recommended interim limit.

Glenmark Pharmaceuticals Inc., USA NDC 68462-864-01 D-0309-2025